Beta-lactamases in Community-acquired Infections: from Lab to Clinic, ESCMID Postgraduate Education Course
10 - 11 March 2009, Ankara, Turkey
Organized by the ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS) and the Infectious Diseases and Clinical Microbiology Specialty Society of Turkey (EKMUD).
Course Objectives
- Raise awareness of the magnitude of antimicrobial resistance
- Increase knowledge about extended-spectrum beta-lactamases
- Increase knowledge about interpretive reading of antimicrobial susceptibility tests
- Demonstrate through case discussions how to choose the right treatment for serious infections
Course Venue
Bilkent Otel, Ankara, Turkey
Target Audience
50-75 infectious disease and clinical microbiology specialists/trainees and epidemiologists
Course Coordinator & Administrative Secretariat
Prof Hakan Leblebicioglu
Department of Infectious Diseases & Clinical Microbiology
Ondokuz Mayis University Medical School, Samsun, Turkey
Phone +90 362 312 1919/2480
hakanomu[at]yahoo.com
Presentations
All presentations are available for ESCMID Members. Please log in or register.
Day 1
Introduction. Hakan Leblebicioglu
Session: Extended-spectrum and other beta-lactamases: still extending
Chair: Gian Maria Rossolini
Evolution of ESBLs. Dora Szabo
ESBLs in the community: the CTX-M dilemma. Haluk Vahaboglu
AmpC-type and carbapenemases. Gian Maria Rossolini
Session: Detection of beta-lactamases
Chairs: Haluk Vahaboglu & Gul Bahar
Phenotypic and genotypic detection of beta-lactamases. Jordi Vila
Automated susceptibility testing systems. Luis Martinez-Martinez
Workshop: Interpretive reading of in vitro antimicrobial test results. Rafael Canton
Session: Preventive strategies: need for speed or wait for resistance
Chair: Javier Garau
Surveillance of resistance & Local and nation-wide antibiotic restriction policies. Salih Hosoglu
Day 2
Case discussion: Controversies about extended-spectrum and AmpC beta-lactamases. Javier Garau
Session: ESBLs: how can we treat?
Chair: Hakan Leblebicioglu
PK/PD parameters for selecting antibiotics for treatment. Dilek Arman
Beta-lactam & beta-lactamase inhibitors. Murat Akova
Carbapenems. Hakan Erdem
Tigecycline. Hasan Salih Zeki Aksu
